ETC-159, an oral selective small molecule inhibitor of porcupine that inhibits Wnt protein (all members) secretion, is another PORCN inhibitor that has demonstrated significant anti-cancer effect in preclinical investigations and has thus been entered into phase 1 clinical trials (43). Here, PORCN is linked to cancer.